GSA Capital Partners’s Protalix BioTherapeutics PLX Stock Holding History

GSA Capital Partners’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-209,292	Closed	-$536K	–	2060
2025 Q1	$536K	Sell	209,292 -96,457	-32%	-$230K	0.05%	761
2024 Q4	$575K	Sell	305,749 -129,464	-30%	-$183K	0.04%	783
2024 Q3	$444K	Buy	435,213 +33,969	+8%	+$35.7K	0.03%	991
2024 Q2	$469K	Sell	401,244 -92,327	-19%	-$109K	0.03%	1009
2024 Q1	$622K	Sell	493,571 -50,667	-9%	-$75.6K	0.05%	754
2023 Q4	$969K	Buy	544,238 +47,457	+10%	+$73.8K	0.08%	414
2023 Q3	$825K	Buy	+496,781	New	+$892K	0.07%	509
2022 Q1	–	Sell	-24,527	Closed	-$20K	–	1735
2021 Q4	$20K	Sell	24,527 -230,344	-90%	-$241K	﹤0.01%	1359
2021 Q3	$339K	Buy	+254,871	New	+$387K	0.03%	939
2021 Q1	–	Sell	-10,042	Closed	-$36K	–	1398
2020 Q4	$36K	Buy	+10,042	New	+$36K	0.01%	1143

Other funds holding PLX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

GSA Capital Partners's PLX Position: Q2 2025 in Review

GSA Capital Partners sold out of Protalix BioTherapeutics (PLX) in Q2 2025, closing a stake of 209,292 shares — an estimated $536K sold.

GSA Capital Partners first reported a position in PLX in Q4 2020 and held it in 10 quarters. The position peaked at $969K in Q4 2023. 63 funds tracked by Wall St. Rank hold PLX as of Q2 2025.

GSA Capital Partners reported no remaining Protalix BioTherapeutics position as of Q2 2025 after selling out during the quarter.
GSA Capital Partners sold 209,292 Protalix BioTherapeutics shares in Q2 2025, an estimated $536K.
GSA Capital Partners first reported a position in Protalix BioTherapeutics in Q4 2020 and held it in 10 quarters.
GSA Capital Partners's Protalix BioTherapeutics position peaked at $969K in Q4 2023.
63 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2025.

Based on GSA Capital Partners's 13F filing for Q2 2025, filed 22 Jul 2025.